<?xml version="1.0"?>
<Articles JournalTitle="International Journal of Hematology-Oncology and Stem Cell Research">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>International Journal of Hematology-Oncology and Stem Cell Research</JournalTitle>
      <Issn>2008-2207</Issn>
      <Volume>17</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="epublish">
        <Year>2023</Year>
        <Month>01</Month>
        <Day>16</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Prognostic Value of the Expression of Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR-1) in Chronic Lymphocytic Leukemia</title>
    <FirstPage>39</FirstPage>
    <LastPage>47</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Aysun</FirstName>
        <LastName>Senturk Yikilmaz</LastName>
        <affiliation locale="en_US">Department of Hematology, Bilkent City Hospital, Y&#x131;ld&#x131;r&#x131;m Beyaz&#x131;t University, Ankara, Turkey</affiliation>
      </Author>
      <Author>
        <FirstName>&#x15E;ule</FirstName>
        <LastName>Bakanay</LastName>
        <affiliation locale="en_US">Department of Hematology, Bilkent City Hospital, Y&#x131;ld&#x131;r&#x131;m Beyaz&#x131;t University, Ankara, Turkey</affiliation>
      </Author>
      <Author>
        <FirstName>Duygu</FirstName>
        <LastName>Avc&#x131;</LastName>
        <affiliation locale="en_US">Department of Hematology, Ankara Numune Training and Research Hospital, , Ankara, Turkey</affiliation>
      </Author>
      <Author>
        <FirstName>Sema</FirstName>
        <LastName>Akinci</LastName>
        <affiliation locale="en_US">Department of Hematology, Atat&#xFC;rk Training and Research Hospital, Ankara, Turkey</affiliation>
      </Author>
      <Author>
        <FirstName>Mesude</FirstName>
        <LastName>Falay</LastName>
        <affiliation locale="en_US">Department of Hematology,  Ankara Numune Training and Research Hospital, , Ankara, Turkey</affiliation>
      </Author>
      <Author>
        <FirstName>G&#xFC;ls&#xFC;m</FirstName>
        <LastName>&#xD6;zet</LastName>
        <affiliation locale="en_US">Department of Hematology,  Ankara Numune Training and Research Hospital, Ankara, Turkey</affiliation>
      </Author>
      <Author>
        <FirstName>&#x130;mdat</FirstName>
        <LastName>Dilek</LastName>
        <affiliation locale="en_US">Department of Hematology, Atat&#xFC;rk Training and Research Hospital, Ankara, Turkey</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2021</Year>
        <Month>06</Month>
        <Day>08</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2021</Year>
        <Month>09</Month>
        <Day>06</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Background: The transmembrane receptor tyrosine kinase-like orphan receptor 1 (ROR1) has acted on the causation and sustentation of mature B cell lymphomagenesis for chronic lymphocytic leukemia (CLL) cells.&#xA0;The aim of this study was to show whether there is a relationship between the level of ROR1 surface expression in CLL cells and disease findings.
&#xD;

Materials and Methods: The level of ROR1 cell surface expression was determined in accordance with the flow cytometric analysis of CLL patients at the first diagnosis time.&#xA0; 2 groups were formed according to the high and low ROR1 levels. The cut-off point to the ROR1 level was calculated for advanced-stage disease by using receiver operating characteristic (ROC) curves. A two-sided p-value &lt;0,05 was considered statistically significant.
&#xD;

Results: 108 CLL cases with a median age of 60 were enrolled. The median percentage of ROR1 cell surface marker positivity in the CD5/CD19 positive leukemic cell was 62%.&#xA0;The CLL cases with high ROR1 levels have thrombocytopenia (p=0.042), anemia (p=0.028), and high beta 2 microglobulin value &#x2265;3 mg/dL (p=0.002) and the need for first-line treatment (p=0.043).
&#xD;

Conclusion: The poor prognostic parameters such as splenomegaly, anemia, higher beta 2 microglobulin levels, intermediate/advanced RA&#x130; stage disease, and need for first-line treatment had associated high-level ROR 1 expression of our CLL patients. It needs to be investigated for its effect on predicting disease burden and aggressiveness with more comprehensive studies on ROR1 expression levels in CLL cases.</abstract>
    <web_url>https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1649</web_url>
    <pdf_url>https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1649/961</pdf_url>
  </Article>
</Articles>
